; (2) is able to build on an existing infrastructure of services and public health research; (3) is located in an area with a high prevalence, or in any area predicted to have a high prevalence, of Lyme disease or other tick- and vector-borne diseases; and (4) has experience with conducting research related to Lyme disease and other tick- and vector-borne diseases. (d) Authorization of appropriations For the purpose of carrying out this section, there are authorized to be appropriated $10,000,000 for each of fiscal years from 2021 through 2026. Amounts appropriated shall be allocated under this section to diseases in a manner that proportionately matches the disease burden of those diseases in the United States, which shall be reassessed and adjusted annually. 4. Cooperative agreements with the Centers for Disease Control and Prevention (a) In general The Secretary, in coordination with the Director of the Centers for Disease Control and Prevention and the heads of other agencies, as appropriate, shall enter into cooperative agreements between the Centers for Disease Control and Prevention and health departments of States, political subdivisions of States, and Indian tribes and tribal organizations, to address Lyme Disease and other tick- and vector-borne diseases, and to support the development and implementation of evidence-based research, interventions, and treatment with respect to— (1) educating and informing the public, based on evidence-based public health research and data, about Lyme Disease and other vector-borne diseases; (2) supporting early detection and diagnosis; (3) supporting prevention; (4) improving treatment; (5) supporting care planning and management for individuals with Lyme disease and other tick- and vector-borne diseases